DeutschNewstral
Article
jdsupra.com on 2020-05-20 05:50
PMPRB News: “significant changes” to be made to draft pricing Guidelines
Related news
- Few significant changes made in final PMPRB Guidelinesjdsupra.com
- Drug pricing in Canada: Changes for the PMPRB with proposed amendments to the Patented Medicines Regulationsjdsupra.com
- Draft revised PMPRB Guidelines released for comment by December 5, 2022jdsupra.com
- PMPRB releases revised draft Guidelinesjdsupra.com
- New PMPRB Guidelines will not be implemented January 1, 2023jdsupra.com
- FCA remits pricing decision on ALEXION’S SOLIRIS to PMPRBjdsupra.com
- PMPRB adopts Amended Interim Guidance pending release of new guidelinesjdsupra.com
- Innovators challenge final PMPRB Guidelines in new Federal Court applicationjdsupra.com
- PMPRB releases draft Guidelines operationalizing amended Patented Medicines Regulationsjdsupra.com
- Consultation on Draft PMPRB Guidelines extended to August 4jdsupra.com
- PMPRB publishes scoping paper for consultation on guidelines, and invites stakeholder feedbackjdsupra.com
- New PMPRB regulations registered, in force July 1, 2022, interim approach to pricing announcedjdsupra.com
- PMPRB news: Upcoming roundtable as first phase of new guidelines consultation, two new appointmentsjdsupra.com
- Final PMPRB Guidelines Releasedjdsupra.com
- Discussion Guide for PMPRB Phase 2 Consultations on New Guidelines outlines proposed new framework for patented medicine price reviewjdsupra.com
- PMPRB extends deadline for consultation on draft Guidelines to January 31, 2020jdsupra.com
- PMPRB extends comment deadline for draft Guidelines; related presentations now publishedjdsupra.com
- PMPRB Update: Jurisdiction extends to CSPs effective June 30; coming into force of Patented Medicines Regulations and Guidelines delayed to January 2022jdsupra.com
- Congress and Administration Consider Significant Drug Pricing Policy Changesjdsupra.com
- 2021 PMPRB Annual Reportjdsupra.com